Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beyond Revlimid: Celgene's 2015 Plan Targets New Business Areas

Executive Summary

Celgene is on a course to transition from a company centered mainly on the multiple myeloma blockbuster Revlimid to a diversified biotech over the next five years. That's the strategy management laid out for investors during an R&D day in New York April 8
Advertisement

Related Content

Revlimid In Limbo: Market Slams Celgene, Physicians And Payers Take Wait And See Approach
Revlimid In Limbo: Market Slams Celgene, Physicians And Payers Take Wait And See Approach
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
Celgene Moves Into Solid Tumors With $2.9 Billion Abraxis Acquisition
Celgene Moves Into Solid Tumors With $2.9 Billion Abraxis Acquisition
Celgene Makes Aggressive Push Into Solid Tumors With $2.9 Billion Abraxis Acquisition
FDA Wants Clinically Meaningful Outcomes, Mortality Measured in IPF Trials
FDA Wants Clinically Meaningful Outcomes, Mortality Measured in IPF Trials

Topics

Advertisement
UsernamePublicRestriction

Register

PS052129

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel